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INTRODUCTION
Most clinical disorders arise from multiple gene-environment
interactions rather than variations in single genes (Wray et al., 2008)
– a particularly important concept when considering neurological
conditions and psychiatric disorders. Even many ‘single gene’
diseases do not manifest in all carriers of a mutation, indicating
that other factors can be involved (Summers, 1996). This complexity
brings into focus the need to find new models to identify the
complex genetic and environmental interactions that contribute to
brain disorders. Of paramount importance, the field requires
pragmatic methods that can readily derive large numbers of
relevant cells from multiple cases and controls, which are needed
to represent the spectrum of variability between individuals.
Accessible non-neural cells like skin fibroblasts or transformed
lymphocytes have been used to identify differences in cell biology
associated with schizophrenia (SZ) and Parkinson’s disease (PD)
(Mahadik and Mukherjee, 1996; Miyamae et al., 1998; Winkler-
Stuck et al., 2004; Hoepken et al., 2008) but the utility of non-neural
cells for understanding the cellular bases of neurological and
neuropsychiatric disorders is limited (Matigian et al., 2008).
Another approach is to develop stem cell models of disease:
embryonic stem (ES) cells carrying genetic mutations have been
isolated after pre-implantation genetic diagnosis (Verlinsky et al.,
2005; Mateizel et al., 2006), and induced pluripotent stem (iPS) cells
have been generated from patients, including those with PD (Park
et al., 2008). However, major challenges remain in applying these
models to the study of sporadic brain diseases, as the models must
be routine and robust as well as informative for the disease process.
The olfactory mucosa, the organ of smell in the nose, is a neural
tissue that is accessible in human adults (Féron et al., 1998) and
demonstrates disease-dependent alterations in cell biology in
Alzheimer’s disease, Rett syndrome, fragile X syndrome and SZ
(Wolozin et al., 1992a; Abrams et al., 1999; Féron et al., 1999; Arnold
et al., 2001; Ronnett et al., 2003; McCurdy et al., 2006). The olfactory
sensory neurons are replaced by neurogenesis that continues
throughout adult life from stem cells on the basement membrane
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SUMMARY
There is a pressing need for patient-derived cell models of brain diseases that are relevant and robust enough to produce the large quantities of
cells required for molecular and functional analyses. We describe here a new cell model based on patient-derived cells from the human olfactory
mucosa, the organ of smell, which regenerates throughout life from neural stem cells. Olfactory mucosa biopsies were obtained from healthy controls
and patients with either schizophrenia, a neurodevelopmental psychiatric disorder, or Parkinson’s disease, a neurodegenerative disease. Biopsies
were dissociated and grown as neurospheres in defined medium. Neurosphere-derived cell lines were grown in serum-containing medium as adherent
monolayers and stored frozen. By comparing 42 patient and control cell lines we demonstrated significant disease-specific alterations in gene
expression, protein expression and cell function, including dysregulated neurodevelopmental pathways in schizophrenia and dysregulated
mitochondrial function, oxidative stress and xenobiotic metabolism in Parkinson’s disease. The study has identified new candidate genes and cell
pathways for future investigation. Fibroblasts from schizophrenia patients did not show these differences. Olfactory neurosphere-derived cells have
many advantages over embryonic stem cells and induced pluripotent stem cells as models for brain diseases. They do not require genetic
reprogramming and they can be obtained from adults with complex genetic diseases. They will be useful for understanding disease aetiology, for
diagnostics and for drug discovery.
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(Mackay-Sim and Kittel, 1991; Leung et al., 2007). Olfactory
mucosa contains stem cells that are multipotent and can be
propagated as stem or progenitor cells in neurospheres, a hallmark
of neural stem cells (Roisen et al., 2001; Murrell et al., 2005; Murrell
et al., 2008; Murrell et al., 2009). They can be proliferated in vitro
and differentiated into multiple cell types including neurons and
glia (Roisen et al., 2001; Murrell et al., 2005; Murrell et al., 2008;
Murrell et al., 2009).
With evidence for disease-related alterations in olfactory
epithelium and the loss of olfaction that is associated with many
neurological diseases, including SZ and PD (Brewer et al., 2003;
Doty, 2009; Haehner et al., 2009; Turetsky et al., 2009), we
hypothesized that olfactory mucosal stem cells derived from SZ
and PD patients would provide an accessible, proliferating
population to investigate the cellular bases of these diseases
(Mackay-Sim and Silburn, 2008). We predicted that olfactory
neurosphere-derived (ONS) cells would exhibit disease-specific
alterations in these two unrelated neurological and neuropsychiatric
disorders: SZ, a highly heritable neurodevelopmental condition
(Raedler et al., 1998), and PD, a neurodegenerative disease that is
heritable in only about 5% of familial cases (Lesage and Brice, 2009).
We examined and compared ONS cells from multiple patients with
SZ and PD to identify aspects of cell biology that were shared by
each group of patients and different from healthy controls.
We report here that ONS cells from SZ and PD patients, when
subjected to gene and protein expression profiling and cell function
assays, revealed different signalling pathways altered in each patient
group, compared with healthy controls. In SZ ONS cells we
predicted and found alterations in cell signalling pathways involved
in cell proliferation, neurogenesis and cell adhesion (Féron et al.,
1999; McCurdy et al., 2006), whereas skin fibroblasts from the same
patients did not show these altered pathways. In PD ONS cells we
predicted and found convergence on molecular pathways previously
associated with this disorder – namely, mitochondrial function,
oxidative stress and xenobiotic metabolism (Henchcliffe and Beal,
2008). These results demonstrate that the ONS cell model is robust
and informative, with the potential for providing a new tool for
studying the mechanisms of human brain disorders and diseases.
RESULTS
We undertook multiple experiments on the 42 ONS cell lines from
patients and controls (SZ, n9; PD, n19; control, n14). We
characterized the phenotype using flow cytometry on a subset of
18 cell lines (SZ, n6; PD, n6; control, n6). As experimental
controls we also characterized fibroblasts from control patients
(n9). Gene expression profiling compared all 42 ONS cell lines
from patients and controls. Protein expression profiling compared
nine ONS cell lines (n3 for each group). Gene and protein
expression profiling was confirmed on two replicate samples of each
cell line, each grown independently. Gene expression differences
were validated for subsets of genes using quantitative reverse-
transcriptase polymerase chain reaction (qRT-PCR). Protein
expression was validated by western blot analysis for one protein
in protein samples from nine ONS cell lines. Pathway analysis of
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Table 1. qRT-PCR confirmation of microarray expression data for selected genes
Illumina qPCR
Gene symbol GenBank P value Fold change P value Fold change
Schizophrenia
AXIN2 NM_004655 0.0153 2.05 0.4690 1.38
CDH2 NM_001792 0.0009 –2.37 0.0350 –2.17
GSK3B NM_002093 0.0280 –1.20 0.0320 –1.28
ITGA8 NM_003638 0.0013 6.93 0.0140 6.65
ITGB1BP1 NM_022334 0.0459 1.92 0.8590 1.04
PIK3R1 NM_181504 0.0035 1.35 0.5200 1.09
PPP2R2B NM_181676 0.0026 –4.26 0.9260 –1.08
WNT5A NM_003392 0.0002 2.07 0.0170 1.94
RGS4 NM_005613 0.0014 –2.93 0.0070 –4.59
GABRE NM_021990 0.0005 1.92 0.0090 1.75
LRP8 NM_033300 0.0329 –1.53 0.3450 –1.30
SLC1A1 NM_004170 0.0053 –2.43 0.0300 –2.38
PARVB NM_001003828 0.0010 –1.44 0.6910 –1.08
LAMA3 NM_198129 0.0021 1.94 0.0100 2.50
RELN NM_005045 0.0130 –4.15 0.0430 –8.33
Parkinson’s disease
GABBR2 NM_005458 0.0006 4.99 0.0140 3.41
GSTM1 NM_000561 0.0011 –7.46 0.0720 –5.92
MGST1 NM_020300 0.0059 –1.82 0.0470 –1.69
PSG4 NM_002780 0.0041 5.42 0.0010 11.73
Comparison of relative gene expression using qRT-PCR to confirm microarray expression levels. Transcripts for re-analysis were selected from those significantly differentially
expressed between patient and controls on the microarray across a range of fold-change differences, with a minimum fold-change difference of 1.2. Fold-change and P values
show patient samples relative to control samples. Fold-change differences were in the same direction in qRT-PCR as on the microarray. qRT-PCR was undertaken on mRNA from the
same samples used for the microarray analysis.
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the differentially expressed genes and proteins was undertaken
using two independent databases: one public and one commercially
available. Assays of six metabolic functions were performed on SZ
and control ONS cells (n9 for each group), and on PD and control
ONS cells (n14 and 16, respectively). Thus, the disease-specific
differences in cell biology were observed across multiple patients
and multiple ONS cell lines for each disease.
Growth, morphology and immunophenotype of ONS cells
ONS cells are derived from neurospheres that form when
dissociated olfactory mucosal cells are grown in a serum-free
medium containing epidermal growth factor (EGF) and fibroblast
growth factor 2 (FGF2) (Fig. 1A). Neurospheres were generated
from all 42 patients and controls, with no obvious disease-related
differences in neurosphere growth and formation. The
neurospheres were dissociated and grown in the presence of serum
as an adherent monolayer of ONS cells (Fig. 1B). For ONS cells,
the fastest growth occurs between 10 to 60 days in vitro (up to
passage 12). At passage 4 (20 days in vitro) the doubling time of
nine control cell lines was 28.3±1.4 hour. All the experiments here
were undertaken on cells at passages 4-8 (up to 40 days in vitro).
We checked chromosomal stability by karyotyping 22 olfactory cell
lines at passages 3-10: all were normal. Two ONS cell lines were
grown continuously for more than 160 days in vitro, through at
least 16 passages. Each cell line reached 95% of its total growth in
60 days (12 passages) and divided only very slowly after 100 days.
We checked gene expression stability in one cell line from passages
7-25. At passages 10, 13, 16, 19, 22 and 25 the gene expression
profile (across the 10,000 expressed genes) was correlated with the
gene expression profile at passage 7, yielding correlation coefficients
of 0.99, 0.98, 0.98, 0.96, 0.94 and 0.94, respectively. This high level
of correlation indicates that ONS cells are quite stable genetically
for many passages and more than 100 days in vitro.
Flow cytometric analysis indicated some heterogeneity in
immunophenotype of the cells in ONS cultures (Fig. 1C,D). The
majority of cells were immunopositive with antibodies to CD105
and CD73. Antibodies to nestin (NES) and OCT4 labelled many
fewer cells at low intensity than did those against CD105 and CD73.
All these proteins are used as markers for other stem cell
phenotypes (CD105 and CD73 for mesenchymal stem cells; NES
Disease Models & Mechanisms 787
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Fig. 1. Phenotype of ONS cells. (A)Olfactory neurospheres
being formed from cells cultured from biopsy of human
olfactory mucosa, grown in serum-free medium containing
EGF and FGF2. (B)Cells grown from dissociated olfactory
neurospheres in a medium containing serum; these are
‘olfactory neurosphere-derived’ (ONS) cells. (C)Typical flow
cytometry results from an ONS cell line, plotting the relative
frequency of cells labelled (y-axis) against fluorescence
intensity (x-axis) for each of the antibodies (name above
panel; antibody-labelled cells in grey; isotype-control cells in
white). (D)Summary data for all ONS cells from patients and
controls. Positive cells are those with antibody fluorescence
greater than isotype controls.
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for neural stem cells; OCT4 for ES cells). The cells were
immunopositive for -tubulin III (TUBB3), a marker for neural
progenitors and developing neurons, but not immunopositive for
SOX2 and several proteins associated with more-differentiated
phenotypes (GFAP, CD45). Analysis of variance indicated
significant differences between groups (P<0.05) for CD105 and
OCT4, and significant pair-wise differences between SZ and PD
for CD105 and TUBB3, and between control and PD cells for
OCT4. Gene expression profiling (below) further described the
phenotype of these cells and the differences between them.
SZ-derived ONS cells displayed altered neurodevelopmental
genes, pathways and function
We used microarray gene expression profiling to test our
hypothesis that we would identify convergent, dysregulated
neuro developmental processes in ONS cells from patients with
SZ. We observed profound and highly reproducible differences
in the transcriptomes of SZ and control ONS cells. Of the 10,515
probes detected on the microarrays of the SZ and control ONS
cells, 16% (1700) were differentially expressed [P<0.05 (Benjamini
and Hochberg multiple testing adjusted P values); supplementary
material Table S1; experiments performed in duplicate]. An equal
number of the genes were overexpressed or underexpressed in
SZ ONS cells compared with control cells, and 12% (219/1702)
were expressed in SZ cells at least twofold more, or less, than in
control cells. Fifteen genes that were differentially expressed on
the microarrays were validated using qRT-PCR and showed
differences between patients and controls (SZ, n9; control, n9)
consistent with the original array findings. These differences were
statistically significant in 9/15 of the transcripts tested by qRT-
PCR (Table 1).
We asked whether differentially expressed genes represented
multiple members of any cell signalling pathways that could
coordinately alter cell function in SZ. Pathway analysis is a statistical
test of the number of differentially expressed genes that contribute
to known cell signalling pathways. For SZ our prediction was that
the differentially expressed genes would be over-represented in
cellular pathways of neurodevelopment. Pathway convergence was
assessed using Ingenuity Pathway Analysis, which identified ten
pathways that were significantly over-represented (P<0.01; Table
2). A second analysis using the public database DAVID identified
five pathways that were significantly over-represented (P<0.01;
Table 2). Both methods of pathway analysis identified the same
essential dysregulation of highly interconnected functions involved
in brain development through the processes of focal adhesion,
axonal guidance and receptor-mediated signalling (supplementary
material Fig. S1). Importantly, five of the pathways identified are
already implicated in SZ (‘Reelin signalling in neurons’, ‘VDR/RXR
activation’, ‘IL-8 signalling’, ‘Glutathione metabolism’, ‘ErbB
signalling’).
We next looked at differences in protein expression in a subset
of patient-derived cells lines (n3 per group). Proteomic analysis
using two-dimensional dye-in-gel-electrophoresis (2D-DIGE)
identified 20 proteins whose expression was significantly altered
in ONS cells from SZ patients compared with controls (P<0.05;
experiments performed in duplicate; Fig. 2). There was a
convergence between gene and protein expression (Table 3). Of
the proteins with significantly altered expression, transgelin 2
(TAGLN2) was selected for western analysis, which confirmed this
protein was reduced in the SZ cell lines compared with controls
(supplementary material Fig. S3).
With the set of functional assays, we demonstrated that the SZ-
derived ONS cells had significantly increased caspase-3/7 activity,
an indicator of apoptosis (P0.028; Fig. 3F). Although this
neurodevelopmental function was altered, there were no differences
from control ONS cells in a range of other metabolic function assays
(Fig. 3). There was no correlation between the results obtained in
any functional assays and age (r2 range 0.00009-0.0722) or cell-line
passage number (r2 range 0.0002-0.063).
In order to test whether the ONS model offers an advantage over
other somatic cells, we next examined the gene expression of skin
fibroblasts obtained from the same SZ patients as the ONS cells.
Relatively few (118) transcripts were differentially expressed
between patient and control fibroblast lines (P<0.05; supplementary
material Table S2). Of these, none was altered twofold or greater.
Ingenuity Pathway Analysis showed no convergence on the
pathways identified in the ONS transcriptome. Two molecular
pathways were significantly over-represented in SZ fibroblasts
compared with control fibroblasts (‘Hypoxia signalling in the
cardiovascular system’, P0.006; ‘Riboflavin metabolism’, P0.009)
but the representation of differentially expressed genes in each
pathway was low: only three and two molecules, respectively. We
dmm.biologists.org788
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Table 2. Cellular signaling pathways altered in schizophrenia
Ingenuity Pathway Analysis (gene expression)
Count P value
Ephrin receptor signaling 28 0.00003
NRF2-mediated oxidative stress response 26 0.0003
Axonal guidance signaling 43 0.001
IL-8 signaling 23 0.002
Virus entry via endocytic pathways 14 0.003
Semaphorin signaling in neurons 10 0.006
Fc  receptor-mediated phagocytosis in
macrophages and monocytes
14 0.006
Glutathione metabolism 10 0.007
Reelin signaling in neurons 12 0.008
VDR/RXR activation 12 0.009
DAVID analysis (gene expression)
Ribosome 21 0.000002
Focal adhesion 38 0.0001
Axon guidance 25 0.001
ErbB signaling pathway 18 0.004
Inactivation of GSK3 by AKT causes accumulation
of -catenin in alveolar macrophages
9 0.008
Ingenuity Pathway Analysis (protein expression)
Glycolysis/gluconeogenesis 4 0.00001
Molecular pathways significantly altered in SZ identified by Ingenuity Pathway
Analysis and DAVID analysis from the 1700 genes and 20 proteins with significantly
altered expression in SZ cells compared with controls. Pathways are identified
statistically using Fisher’s exact test to calculate a probability (P value) of finding the
number of genes or proteins on the differentially expressed list (Count) compared
with the number of molecules in the pathway and the total numbers of genes or
proteins sampled.
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conclude that skin fibroblasts are not informative compared with
ONS lines generated from the same patient-control cohort.
PD-derived ONS cells displayed altered metabolic genes,
pathways and functions
PD provides an obvious clinical contrast to SZ, on many levels. It
was predicted that we would identify different convergent,
dysregulated metabolic processes in ONS cells from patients with
PD. Again, we found profound differences in the transcriptomes
of PD and control ONS cells. Five percent of the probes (514/10300)
were significantly differently expressed in PD compared with
control cells (P<0.05; supplementary material Table S3). An equal
number of genes were overexpressed or underexpressed in PD ONS
cells compared with control cells, and 8% (43/514) were expressed
in PD cells at least twofold more, or less, than in controls. Four
genes that were differentially expressed on the microarrays were
selected for verification of expression using qRT-PCR (PD, n19;
control, n13) and a high level of agreement was found between
the qRT-PCR and microarray results (Table 1).
Pathway analysis using Ingenuity Pathway Analysis and DAVID
identified eight cell pathways that were significantly over-
represented among the differentially expressed transcripts (P<0.01;
Table 4). Our prediction was that PD cells would demonstrate
differences in mitochondrial function, oxidative stress and
xenobiotic metabolism. This was borne out by significant over-
representation of genes in highly inter-connected pathways,
including four involved in oxidative stress and xenobiotic
metabolism (‘NRF2-mediated oxidative stress response’, ‘Aryl
hydrocarbon receptor signalling’, ‘Glutathione metabolism’,
‘Xenobiotic metabolism signalling’; supplementary material Fig. S2),
exemplified by the significant downregulation of glutathione
transferases (GSTM1, MGST1) in the PD cells (Table 1).
Independent examination of proteins expressed in three ONS
cell lines derived from PD patients revealed 11 proteins that were
Disease Models & Mechanisms 789
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Fig. 2. Examples of differentially expressed proteins. Each pair of columns
compares protein spots in 2D-DIGE gels from three patients and three
controls. Images of spots from two gels per individual, using Cy3 dye and Cy5
dye, are illustrated consecutively for each of three individuals per group in
each column. Each pair of columns represents patients on the left and controls
on right. The graphs below show normalized spot volume for each of the
spots shown above (mean ± s.e.m.). Lines drawn on gels indicate the regions
over which spot volume was calculated. Spots were normalized to intensity of
same spot identified in a mixture of proteins from all cells, run in the same gel
and imaged using Cy2 dye. (A)GSTO1 is underexpressed in SZ (P0.001).
(B)STMN1 is overexpressed in SZ (P0.001). (C)GSTO1 is underexpressed in PD
(P0.001). (D)P4HB is overexpressed in PD (P0.002).
Table 3. Protein and gene expression in Schizophrenia and
Parkinson's disease
Protein expression mRNA expression
Gene symbol
Fold
change P value
Fold
change P value
Schizophrenia
ABI1 –2.3 0.01 1.13 0.01
ACTB –1.3 0.0004 –1.09 0.005
DPYSL2 –1.6 0.02 –1.06 0.43
ESD –2.6 0.04 1.07 0.13
GAPDH –1.35 0.003 –1 0.95
GSTO1 –2.8 0.001 –1.01 0.96
HNRNPA1 1.45 0.01 1.21 0.26
LMNA –1.3 0.02 1.03 0.74
P4HA1 –1.3 0.01 1.01 0.97
PGAM1 –1.35 0.001 –1.11 0.33
PGK1 –1.55 0.001 –1.13 0.23
STMN1 1.85 0.0003 –1.26 0.31
TAGLN –1.6 0.01 –1.12 0.005
TAGLN2 –1.5 0.02 –1.19 0.06
TPI1 –1.35 0.03 –1.07 0.38
TPM1 –1.85 0.01 –1.33 0.02
TPM2 –1.55 0.01 –1.05 0.05
TRA1 1.2 0.02 1.01 0.89
TTN 1.45 0.03 1.06 0.67
UCHL1 1.7 0.03 –1.01 0.99
Parkinson's disease
ANXA4 –1.2 0.04 1.05 0.64
CNN1 2.1 0.01 1.35 0.43
DPYSL2 –1.2 0.04 –1.12 0.06
GSTO1 –3.7 0.0006 –1.04 0.65
LMNA –1.2 0.04 –1.04 0.51
NQO1 –1.9 0.0002 –1.31 0.02
P4HA2 1.4 0.01 1.26 0.01
P4HB 1.2 0.03 1.03 0.65
PGK1 –1.2 0.02 1.12 0.32
UCHL1 2.5 0.01 –1.51 0.18
VCP 1.2 0.03 –1.01 0.93
Genes whose protein expression was differentially expressed in SZ and PD compared
with the level of gene expression measured by mRNA expression. Relative protein
expression (patient vs control) was quantified with 2D-DIGE in replicate in two
independent samples from three patients from each group and three controls.
Relative mRNA expression was quantified on the Illumina BeadArray with ONS cells
from 42 patients and controls in two independent samples. ‘Fold-change’ and ‘P
values’ show patient samples relative to samples from healthy controls.
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significantly altered compared with controls (Table 3). Western
analysis showed TAGLN2 protein was expressed more in PD ONS
cells compared with controls (supplementary material Fig. S3). As
with SZ ONS cells, there was agreement between protein and
transcriptome expression. This agreement was further evident in
the Ingenuity Pathway Analysis of the proteins, which identified
four pathways that overlapped with the pathways identified from
the gene expression analysis (Table 4). Proteomic and gene
expression pathways clearly converged on oxidative stress and
metabolic pathways in the ONS cells derived from PD patients.
We examined the metabolic function assays of the ONS cells
from PD patients to validate our predictions of abnormal oxidative
function, and confirmed these disease-associated differences in cell
function assays (Fig. 3). The PD cells demonstrated significant
reductions in glutathione (reduced glutathione content, P0.042;
Fig. 3G) and metabolic activity (MTS metabolism, P0.007; Fig.
3H). There was no correlation between the results obtained in any
functional assay and age (r2 range 0.0004-0.04) or cell line passage
number (r2 range 0.0006-0.2).
DISCUSSION
We show here that human olfactory neurosphere-derived cell
lines  (ONS cells) demonstrate alterations in gene expression,
protein expression and cell function, including dysregulated
neurodevelopmental pathways in SZ and dysregulated
mitochondrial function, oxidative stress and xenobiotic metabolism
in PD. These disease-specific differences conform to current broad
hypotheses about the aetiologies of these diseases but also provide
specific candidate genes and cell pathways for future investigation.
Human ONS cells therefore provide informative cellular models
for SZ and sporadic PD. By contrast, fibroblasts from SZ patients
and healthy controls showed few gene expression differences,
confirming our previous observations (Matigian et al., 2008).
Diseases like SZ and sporadic PD are difficult to model because
of the complex interactions between uncertain environmental
exposures and unknown genetic risk factors. To address this,
accessible cells like lymphocytes and skin fibroblasts have been used
to identify patient-control differences. For SZ and PD these
differences have been modest, perhaps because these cell types do
not reflect tissue-specific differences important for brain function
(Matigian et al., 2008; Wang et al., 2009). As a neural tissue, the
olfactory mucosa might be more relevant, as demonstrated
previously by disease-associated differences in cell functions
(Wolozin et al., 1992a; Féron et al., 1999; McCurdy et al., 2006) and
tissue structure (Arnold et al., 2001; Ronnett et al., 2003). ONS
cells provide new patient-derived, stem-cell-based models of
neurological disease that are accessible in all adults and provide
new routes for understanding the pathogenesis of complex diseases.
dmm.biologists.org790
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Fig. 3. Functional assays of ONS cells. (A-F)SZ
versus control. All assays were performed on the
same cells: SZ, black bars (n9); control, white bars
(n9). Caspase-3/7 activity was significantly
increased in SZ (P0.023). (G-L)PD versus control.
All assays were performed on the same cells: PD,
black bars (n14); control, white bars (n16).
Reduced GSH (glutathione) content was
significantly decreased (P0.042). MTS metabolism
was significantly reduced (P0.007).
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They can be grown in standardized conditions, frozen, banked,
thawed, and regrown in quantity for gene and protein expression
analyses and functional investigations.
It is expected that susceptibility to disease-risk environmental
exposures in SZ and PD is related to the genetic background of
cases compared with controls. This study confirmed the hypothesis
that patients would share a common set of altered cellular pathways
and gene networks that could lead to a disease phenotype in ONS
cells. These models provide opportunities for investigating the
effects of environmental exposures on cells of different genetic
background to further understand gene-environment interactions
in SZ and PD.
Patient-derived ONS cells provide disease-relevant findings
even in a relatively undifferentiated state. For this study we grew
the ONS cells in standard culture conditions to obtain enough for
mRNA, protein and functional analyses as a baseline for future
studies of differentiated cells. ONS cells might be even more
informative when differentiated into specific neural lineages
(Murrell et al., 2005; Murrell et al., 2008; Murrell et al., 2009).
Because of their accessibility and relative ease of generation it
should be feasible to grow ONS cells from enough patients to
investigate cellular sequelae of clinical subtypes (e.g. tremor-
dominant or non-dominant PD). ONS cells are a potentially
unlimited source of renewable patient-derived cells for the
development of new diagnostics and high-throughput drug
screening.
Technical considerations
Human olfactory sensory neurons are continually regenerated
throughout life (Murrell et al., 1996) from stem or progenitor cells
in the olfactory epithelium (Chen et al., 2004; Leung et al., 2007).
Olfactory neuroblasts (Wolozin et al., 1992b) and neurospheres
(Roisen et al., 2001; Murrell et al., 2005) can be grown from the
human olfactory mucosa. In the present study, olfactory
neurospheres were generated from olfactory mucosa biopsies by
growing the dissociated cells in serum-free medium containing
EGF and FGF2. Olfactory neurospheres produced in this way
contain multipotent progenitor cells capable of differentiating into
cells of the neural lineage (Roisen et al., 2001; Murrell et al., 2005;
Othman et al., 2005) and multiple other cell types (Murrell et al.,
2005). Neurosphere-derived cells are generated by dissociating
neurospheres and propagating the cells in a serum-containing
medium as an adherent monolayer. In this medium, human ONS
cells shared many characteristics with, but were not identical to,
bone-marrow stromal cells, including sharing many surface
antigens and expressed genes (Delorme et al., 2010). In the present
study, flow cytometric analysis revealed low or absent levels of
expression of the neural stem or progenitor markers NES and
TUBB3 (low) and SOX2 (absent), with negligible expression of
the astrocyte marker GFAP. They expressed high levels of two
cell-surface markers of bone-marrow stromal or stem cells, CD73
and CD 105, and a low level of expression of a pluripotency
marker, OCT4. The ONS cells from patients and controls were
similar in morphological and immunological phenotype,
consistent with an ‘ecto-mesenchymal’ stem or progenitor cell
population (Delorme et al., 2010). Despite this relatively
undifferentiated state, the ONS cells  demonstrated significant
disease-related differences. These differences might be magnified
or altered if the ONS cells were differentiated into the relevant
cells of the nervous system (Murrell et al., 2005), and this ability
to differentiate demonstrates their advantage over other adult-
derived cells such as fibroblasts and lymphoblasts. In this sense,
the current study provides a baseline for future studies of
differentiated cells derived from ONS cells.
Although we favour the hypothesis that genetic background is
the major contributor to the disease-related differences we
observed, they might be caused in total or in part by epigenetic
alterations brought about by the disease process or by therapeutic
drugs. Without pre- and post-diagnosis samples these issues cannot
be resolved. We consider epigenesis unlikely because the patients
received a variety of combinations of medications and doses and
we found no significant effects of medication on gene expression
or cell function. Additionally, the negligible patient-control
difference in fibroblast gene expression suggests that systemic
disease effects or systemic drug effects are minimal, at least in SZ.
One cannot rule out tissue-specific effects that might manifest in
ONS cells. The patient and control groups were not exactly
matched for sex and age. This might have biased the results for the
PD sample because the 14 controls included some age- and sex-
matched to the SZ patients.
The reliability of the gene and protein expression data was
verified in several ways. Gene expression was independently
verified using qRT-PCR for selected mRNAs, and protein
expression was verified by western analysis of one protein in
independent ONS cell samples. The concordance between mRNA
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Table 4. Cellular signaling pathways altered in Parkinson’s disease
Count P value
Ingenuity Pathway Analysis (gene expression)
NRF2-mediated oxidative stress response 13 0.0002
Aryl hydrocarbon receptor signaling 11 0.0003
Glutathione metabolism 7 0.0003
Purine metabolism 16 0.002
Arginine and proline metabolism 7 0.002
LPS/IL-1-mediated inhibition of RXR function 11 0.004
Xenobiotic metabolism signaling 13 0.004
Neuropathic pain signaling in dorsal horn
neurons
7 0.007
DAVID analysis (gene expression)
Glutathione metabolism 8 0.0003
Purine metabolism 13 0.004
Ingenuity Pathway Analysis (protein expression)
NRF2-mediated oxidative stress response 3 0.0003
Hypoxia signaling in the cardiovascular system 2 0.001
Arginine and proline metabolism 2 0.001
Aryl hydrocarbon receptor signaling 2 0.005
Molecular pathways significantly altered in PD identified by Ingenuity Pathway
Analysis and DAVID analysis from the 514 genes and 11 proteins with significantly
altered expression in PD cells compared with controls. Pathways are identified
statistically using Fisher’s exact test to calculate a probability (P value) of finding the
number of genes or proteins on the differentially expressed list (Count) compared with
the number of molecules in the pathway and the total numbers of genes/proteins
sampled.
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and protein levels provides counter-verification. The corresponding
mRNAs for 21 (68%) proteins were overexpressed or
underexpressed in the same direction, and six of these differences
(19%) were statistically significant (P≤0.05) for both mRNA and
protein. This level of concordance between mRNA and protein
expression falls within the expected modest correlation reported
in other cells, varying between 20% and 70% (Chen et al., 2004;
Nie et al., 2006; Pascal et al., 2008).
ONS cells as a model for SZ
SZ is considered a disorder in which brain development is altered
by genetic and environmental factors (Harrison, 1999; Marenco
and Weinberger, 2000; Lewis and Levitt, 2002; McGrath et al.,
2003b). The current data provide numerous lines of evidence
for  altered molecular pathways that are involved in
neurodevelopment, including cell proliferation, adhesion,
migration and cell death. Importantly, several pathways confirm
multiple independent observations in SZ. Of particular note are
four genes – RELN, RGS4, ERBB3 and GSK3B – whose expression
was downregulated in ONS cells from SZ patients. There is
consistent and repeatable evidence that gene and protein
expression of these four genes are downregulated in post-mortem
brain from SZ patients (Impagnatiello et al., 1998; Guidotti et al.,
2000; Kozlovsky et al., 2000; Fatemi et al., 2001; Hakak et al., 2001;
Mirnics et al., 2001; Aston et al., 2004; Kozlovsky et al., 2004;
Erdely et al., 2006; Colantuoni et al., 2008). Several of these genes
are involved in highly inter-related signalling pathways in which
other genes are affected. GSK3, which is downstream of
neuregulin-ErbB and RELN signalling, is a potential regulator of
several signalling pathways in SZ (Lovestone et al., 2007). All three
pathways were significantly dysregulated in SZ ONS cells. RELN
and the gene encoding the RELN receptor, LRP8, were
significantly downregulated in ONS cells. RELN is an extracellular
matrix protein that stabilizes neuronal microtubules to regulate
neuronal migration (Hiesberger et al., 1999) and the structure of
dendritic trees (Trommsdorff et al., 1999). RELN is reduced in
the prefrontal cortex of humans with SZ (Impagnatiello et al.,
1998). RELN binds integrin 31 (Schmid et al., 2005), which was
also downregulated (supplementary material Table S1), suggesting
a coordinated dysregulation of the RELN signalling pathway in
cells from individuals with SZ, as confirmed by the pathway
analysis. There is emerging evidence for dysregulated ErbB
signalling in SZ (Corfas et al., 2004). ErbB3 is reduced in the
prefrontal cortex in SZ (Tkachev et al., 2003) and the gene
encoding its ligand, neuregulin-1 (NRG1), was identified in gene
association studies in SZ (for a review, see Corfas et al., 2004).
ERBB3 gene expression was reduced in the SZ-derived ONS cells,
and a high level of convergence from multiple molecules in the
ErbB-neuregulin pathways was observed in the ONS model.
Our data direct attention to other disruptions in the highly
interconnected molecular pathways affecting brain development that
have not previously been implicated in SZ. The ‘Ephrin signalling’
pathway was the most affected pathway in ONS cells in SZ. Ephrin
signalling is essential for cell and axon migration and regulates
synaptic plasticity (Martinez and Soriano, 2005). In the SZ ONS cell
lines the expression of three integrins was significantly altered
(supplementary material Table S1) and ‘Focal adhesion’ was identified
in the pathway analysis. A recent analysis of the ‘integrin adhesome’
identified 94 ‘intrinsic components’ (Zaidel-Bar et al., 2007). Of these,
19 (20%) had altered expression in ONS cells from SZ patients.
The results provide support at a cellular level for a nexus
between neurodevelopment and prenatal risk factors for SZ. First,
prenatal infection by certain viruses increases the risk of SZ
(Brown, 2006) and ‘Virus entry via endocytotic pathways’ was
significantly altered in ONS cells. Second, raised maternal
cytokines, including interleukin 8 (IL-8), are associated with
increased risk of SZ (Brown et al., 2004), and ‘IL-8 signalling’ was
significantly disrupted in ONS cells. Finally, reduced maternal and
newborn levels of vitamin D are associated with increased risk of
SZ (McGrath et al., 2003a; McGrath et al., 2004). ‘VDR/RXR
activation’ was significantly altered in ONS cells. Involvement of
VDR (the vitamin D receptor) is of interest because there is robust
evidence from rodent models that reduced prenatal levels of
vitamin D alter the developing and adult brain (Eyles et al., 2003;
Feron et al., 2005). A plausible argument can also be made for
dysregulation of retinoid signalling in the aetiology of SZ
(Goodman, 1998; LaMantia, 1999), which interacts with vitamin
D signalling via the retinoid X receptor (RXR). The altered pathways
in ONS cells in SZ provide a plausible connection between cellular
processes and susceptibilities to these environmental risks.
Skin fibroblasts are another easily accessible source of patient
cells that have been used as cellular models of SZ (Mahadik and
Mukherjee, 1996). Our previous observation was that fibroblasts
do not show robust patient-control differences in SZ (Matigian et
al., 2008). In the present study, we found small differences in gene
expression in SZ fibroblasts compared with controls, with only 118
genes significantly differentially expressed, compared with 1700 in
the ONS cells. Similarly, a recent study found no significant
differences in gene expression and only 16 proteins differentially
expressed in skin fibroblasts (Wang et al., 2009).
ONS cells as a model for PD
PD is a heterogeneous movement disorder with various degrees of
tremor, rigidity and slowness of movement that has a varying age
of onset. The majority of cases of PD are idiopathic, likely arising
from different combinations of genetic and environmental factors
(Benmoyal-Segal and Soreq, 2006). Mutations in the PARK genes
lead to rare, familial, mendelian parkinsonism and have provided
convergence on cellular processes that might be defective in all PD
sufferers (Lesage and Brice, 2009). These include mitochondrial
dysfunction and oxidative stress, disruption of the ubiquitin-
proteasome system, and the aggregation of abnormally folded
proteins such as -synuclein (SNCA) (McNaught and Olanow,
2006). Consistent with these predictions, ONS cells derived from
PD patients shared parallel dysregulation of processes involved in
metabolic and oxidative stress. Crucially, many of the PARK genes
and the identified cellular processes are interlinked. For example,
several of the PARK gene products are located in, or can be
associated with, the mitochondria (e.g. SNCA, Parkin, PINK1, DJ-
1, LRRK2 and HTR2A) (Henchcliffe and Beal, 2008); others play
pivotal roles in the proteasome pathway (Parkin and UCHL1) and
the cellular response to oxidative stress (DJ-1, HTR2A and SNCA).
These PD-associated cellular processes are targets for toxins that
induce parkinsonism in animals (Jenner, 2008), and they are also
implicated in toxicological effects of multiple environmental factors
identified from population studies of human PD. For example,
dmm.biologists.org792
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exposure to environmental toxins such as pesticides appears to
increase the risk for PD, whereas cigarette smoking and caffeine
consumption are less common in patients; the impact of these risk-
altering exposures is also likely to depend on an individual’s genetic
make-up (Mellick, 2006).
We note that the dominant signalling pathways altered in the
patient-derived ONS cells in PD are interconnected and associated
with mitochondrial dysfunction, oxidative stress and xenobiotic
metabolism, as demonstrated in evidence from gene expression,
protein expression and functional assays. Some of these pathways
were identified in post-mortem studies: gene expression profiling
of occipital cortex identified significant alteration in the ‘NRF2-
mediated oxidative stress response’ pathway and similar profiling
of the substantia nigra identified significant alteration in ‘Aryl
hydrocarbon receptor signalling’ in PD (Sutherland et al., 2009).
NRF2 and ARH are transcription factors that induce expression of
cytoprotective genes in response to xenobiotics, including enzymes
of glutathione metabolism (Denison and Nagy, 2003; Cuadrado et
al., 2009), illustrating the interdependence of many of the pathways
identified in the ONS cells. Further agreement with post-mortem
data is the finding of significant alteration in ‘Purine metabolism’
that is also seen in Brodmann area 9 in PD brains (Sutherland et
al., 2009). Functional analyses confirmed significant reduction in
glutathione metabolism and mitochondrial function in cells from
PD patients compared with controls. Additionally, ten genes with
differential expression in ONS cells are also reported as up- or
down-regulated in brains of PD patients compared with controls.
METHODS
Participants and nasal biopsies
All donor tissue and information were obtained with the informed
consent of the participants prior to their involvement in the study
and all procedures were in accordance with National Health and
Medical Research Council Code of Practice for Human
Experimentation, and approved by the Griffith University Human
Experimentation Ethics Committee and the Wolston Park Hospital
Institutional Ethics Committee. Patients with SZ (n9) or PD (n19)
were recruited from consumer groups and through research-
participant registers maintained by the Queensland Centre for
Mental Health Research and the Queensland Parkinson’s Project.
Controls (n14) were recruited from the general population. For
the cohort of patients and controls concerning SZ, participants were
interviewed with the Diagnostic Interview for Psychosis (Castle et
al., 2006). In addition, the hospital records for the patients were
examined in order to confirm diagnoses according to DSM IV
criteria. For the cohort of patients and controls concerning PD, the
patients were diagnosed according to standard clinical evaluation
by a qualified neurologist with experience in movement disorders,
and both patients and controls completed a questionnaire to
exclude the possibility of undiagnosed PD in controls. None of the
healthy controls was on psychotropic or PD medication. Details of
age, medications and smoking status are given in supplementary
material Table S4. The nasal biopsies were collected as an outpatient
procedure as described previously (Féron et al., 1998).
Cell culture
The biopsies were initially received in cold Dulbecco’s Modified
Eagle Medium/Ham F-12 (DMEM/F12; JRH Biosciences)
containing 10% FBS (GibcoBRL) and 1% streptomycin-penicillin
(GibcoBRL). Olfactory cell suspensions were generated by digestion
with dispase II (Boehringer; 2.4 units/ml, 45 minutes, 37°C) and
collagenase H (Sigma; 0.25 mg/ml, 10 minutes, 37°C) accompanied
by mechanical trituration, as described previously (Murrell et al.,
1996; Murrell et al., 2005). The primary cultures were grown for 3
days in DMEM/F12 supplemented with 10% FBS before passaging
into flasks (Nunclon) pretreated with 1 g/cm2 poly-L-lysine
(Sigma, P6282) and culturing in DMEM/F12 containing EGF (50
ng/ml, Sigma) and FGF2 (25 ng/ml, Sigma). Neurospheres formed
initially from cell clusters attached to the culture dish surface but
detached when they reached about 100 m in diameter. The free-
floating neurospheres were harvested every second day from the
medium change. These were dissociated with trypsin, replated at
4000 cells/cm2 into 75 cm2 flasks and cultured in DMEM/F12 with
10% FBS. These neurosphere-derived (ONS) cells were then
expanded by passage and banked down in aliquots after harvest by
storage in liquid nitrogen with 90% FBS and 10% dimethyl sulfoxide
(Sigma). Frozen aliquots of ONS cells were used as the starting point
for all the experiments described: phenotyping, gene and protein
expression and functional assays. All cultures were grown under
standard conditions on tissue culture plastic in DMEM/F12
supplemented with 10% FBS at 37°C and 5% CO2. Frozen aliquots
of ONS cells are available from the National Centre for Adult Stem
Cell Research (http://www.griffith.edu.au/stem-cells), subject to
patient consent, an appropriate Material Transfer Agreement, and
payment of shipping and handling fees.
Flow cytometry
ONS cells were fixed in paraformaldehyde (4% in HBSS) for 10
minutes at room temperature (RT). Approximately 1105 cells were
washed twice with HBSS and incubated for 30 minutes at RT in
0.2 ml HBSS containing 1% BSA, 1% NGS and 0.1% Triton-X 100
together with the antibodies listed below. Cells were washed twice
in HBSS-1%BSA and incubated for 30 minutes at RT with 1:400
dilution of the appropriate secondary antibody (below). After two
washes, the cells were resuspended in washing buffer and analysed
by flow cytometry (BD FACSAria flow cytometer). Isotype-
matched controls were run in parallel for all antibodies. See
supplementary material Table S5 for details of antigen, conjugate,
dilution and supplier. Cells were considered immunopositive if their
fluorescence was above the most fluorescent cells in the isotype-
control sample. For each sample, the percentage of immunopositive
cells was calculated and the groups were compared by Kruskal-
Wallis one-way ANOVA because of unequal group variances.
Dunn’s multiple comparison tests were used to compare pairs of
groups.
Gene expression profiling
Cell lines from 42 participants were grown in at least duplicate
and profiled using the Illumina Beadarray Ref8v2 Chips, producing
88 gene expression profiles. Microarray data are available in the
ArrayExpress database (http://www.ebi.ac.uk/arrayexpress) under
accession number E-TABM-724. Cells expressed approximately
10,000 of the 22,185 transcripts represented by probes on the
chips. The duplicates (biological replicates) for each cell line
provided a quantitative measure of the reproducibility of the full
process to generate the gene expression profile: cell culture, RNA
Disease Models & Mechanisms 793
Stem cell model for brain disorders RESEARCH ARTICLE
D
ise
as
e 
M
od
el
s &
 M
ec
ha
ni
sm
s  
    
   D
M
M
extraction and microarray hybridization. The correlation between
the raw fluorescence values of biological replicates was extremely
high (r2>0.98 for all 42 cell lines), giving confidence that observed
differences in gene expression among different cell lines were
individual- and disease-associated and not due to technical
factors.
ONS cells were grown until 80-90% confluent to assure similar
growth phase and optimized mRNA yield. Total RNA was isolated
using QIAGEN RNeasy Mini Kit using an on-column DNase I
treatment. All RNA preparations were quantified using a Nanodrop
ND1000 and checked with an Agilent 2100 Bioanalyser (RNA nano
chips): only samples with RNA integrity number (RIN)>9 were
accepted for RNA amplification. 500 ng of each RNA sample was
amplified using the Ambion Illumina RNA Amplification Kit with
biotin UTP labeling (Ambion, Inc.). Column-purified samples were
subjected to in vitro transcription using T7 RNA polymerase for
4 hours to synthesize biotin-labeled cRNA. The cRNA was then
column-purified prior to quantification of size and yield using an
Agilent 2100 Bioanalyser. A total of 750 ng of cRNA was hybridized
to human whole-genome Illumina Human-Refseq8 v2 BeadChips
(Illumina, Inc.). These slides were scanned on an Illumina
Beadstation and bead summarization was performed using
BeadStudio Version 3.1.7 (Illumina, Inc.). After summarization, the
raw data were exported from BeadStudio with no additional
processing. The data from BeadStudio were imported into
R/BioConductor using the readBead function from the
BeadExplorer package (Elvidge, 2006). Background adjustment and
quantile normalization (Bolstad et al., 2003) was performed using
algorithms within the Affymetrix package (Gautier et al., 2004)
(function: bg.adjust and normalize.quantiles). The normalized data
were exported from R/BioConductor using write.beadData function
for further analysis using Genespring GX 7.3.1. software (Agilent
Technologies). Genes were initially filtered using Illumina detection
score. The detection score represents the confidence that a given
transcript is expressed above the control signal. A gene (probe) was
included in further analysis if it had a detection score ≥0.99 in both
biological replicate samples and in >25% of individuals within the
disease group (PD, 5/19; SZ, 3/9) or the control group (4/19). This
procedure generated a list of genes expressed in the cells. To
determine genes that were differentially expressed in disease and
control samples, the gene list was subjected to a parametric two-
way ANOVA (P≤0.05) with disease status and replicate as main
effects. The analysis was repeated for each disease compared with
control. The P values were adjusted for multiple testing using the
Benjamini and Hochberg false discovery rate method. The
advantage of this analysis was the identification of genes whose
expression was not altered with biological replicate, providing a
list of genes that were differentially expressed in each disease
compared with controls.
The lists of differentially expressed genes for each disease were
then subjected to pathway ‘over-representation’ analysis using
‘Ingenuity Pathway Analysis’ (IPA) 6.0 (Ingenuity Systems,
http://www.ingenuity.com). Over-representation is a measure of the
probability that a gene list contains more members of a biochemical
pathway than would be expected by chance, given the number of
theoretical members in a pathway, the number of members in the
list of genes of interest, and the number of genes used to generate
the list of interest (i.e. the probes on the Illumina Ref8v2 BeadChip).
This probability is determined by a right-tailed Fisher’s exact test.
The criterion for significance was 0.01. Pathway analysis was
also undertaken using the public database ‘Database for Annotation,
Visualization and Integrated Discovery’ (DAVID) (Dennis et al.,
2003). DAVID calculates a probability (EASE score) of genes of
interest to be represented on pathways annotated by Kyoto
Encyclopedia of Genes and Genomes (http://www.genome. jp/
kegg/) or Biocarta (http://www.biocarta.com). The EASE score is
calculated using the distribution of the Jackknife Fisher exact
probability distribution, and provides a robust analysis of pathways.
The criterion for significance was 0.01.
qRT-PCR confirmation of gene expression
cDNA was synthesized from 2 g of total RNA extracted from ONS
cells using Superscript VILO cDNA Synthesis Kit (Invitrogen)
according to the manufacturer’s protocol. All qRT-PCR reactions
were carried out using the commercial master mix Sensimix HRM
with Evagreen dye (Quantace, UK). Reactions were performed on
a RotorGene 6000 system (Corbett Technologies, Australia) using
5 l of cDNA (1:10 dilution), and 0.5 M of gene-specific primers
to a total reaction volume of 15 l. Cycling conditions were as
follows: 10 minutes at 95°C followed by 40 cycles with denaturation
for 15 seconds at 95°C, annealing for 10 seconds at 55-58°C and
elongation for 10 seconds at 72°C. For annealing temperature and
primer sequence see supplementary material Table S6. Melting
curves were generated after each run to confirm a single PCR
product. All reactions were performed in triplicate and in each run
an internal standard curve were used to assign relative
concentrations to the amplicons. All qRT-PCR primers were
designed using ExPrimer (http://exprimer.ibab.ac.in) and Primer3
(http://frodo.wi.mit.edu/), and were synthesized by Sigma-Aldrich.
Sequences and exon information used for primer design were
obtained from public databases (GenBank, NCBI and Ensembl).
BLAST searches were performed to confirm the total gene
specificity of the primer sequences. Fluorescence data were
converted into cycle threshold measurements using the RotorGene
6000 series software version 1.7. The data were analysed using REST
2008 software (http://www.gene-quantification.info/), where
relative expression of target mRNA was normalized against EEF1A1
and quantified using a relative quantification approach with
efficiency correction (Pfaffl, 2001; Pfaffl et al., 2002). EEF1A1 was
chosen as it displayed the least variation within the microarray
experiments. The data were compared statistically by pair-wise
fixed reallocation randomization test (Pfaffl et al., 2002).
Protein expression profiling
Three ONS cell lines were selected from each group of control, PD
and SZ samples. Cell lines used were: 100030003, 100030008 and
100070001 from the control group; 300020003, 300020004 and
300020005 from the SZ group; and 200050005, 200060005 and
200060007 from the PD group. Proteins extracted from these were
subjected to 2D-DIGE to identify patient-control differences in
protein expression. For each analysis, replicate gels were made from
two protein samples from the same aliquot of cells and then each
analysis was repeated on a second aliquot of cells grown
independently. Reagents were sourced from GE Healthcare, UK
(DIGE CyDyes, 2D Quant and 2D Cleanup Kits, urea, thiourea,
CHAPS, DTT, Immobilized pH Gradient Strips), Fluka (Coomassie
dmm.biologists.org794
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G-250) and Sigma-Aldrich (CHCA matrix, ammonium
bicarbonate, and peptide calibrants ACTH and angiotensin II).
ONS cells from confluent T175 flasks were washed with PBS
and then resuspended in 0.5 ml of DIGE lysis buffer (7 M urea,
2 M thiourea, 4% CHAPS, 30 mM Tris). Samples were sonicated
310 seconds on ice with a Branson sonicator (output 2, constant)
and centrifuged. Supernatant was transferred to new tubes and
samples precipitated with a 2D Cleanup Kit (GE Healthcare)
according to the manufacturer’s instructions. Samples were
resuspended in 50 l of DIGE lysis buffer and pH checked (all
approximately pH 8.5). Protein concentrations were determined
using a 2D Quant Kit (GE Healthcare) according to the
manufacturer’s directions but halving all reaction volumes. DIGE
labeling was performed using a CyDye DIGE Fluors minimal
labeling kit (GE Healthcare) with minor modifications: for each
sample 35 g of protein was labeled with 400 pmol of Cy3 and
(separately) Cy5 in a total volume of 20 l. A pooled aliquot
containing 38.5 g of protein from each sample was bulk labeled
with Cy2 using the same ratio of 35 g of protein to 400 pmol of
CyDye. Labeling was conducted on ice and in the dark for 30
minutes, and quenched by the addition of 10 mM lysine (1 l) on
ice for 10 minutes. Each sample was then diluted with an equal
volume of 2 sample buffer (7 M urea, 2 M thiourea, 4% CHAPS,
80 mM DTT, 2% pharmalytes). Samples were then pooled as needed
for 2D electrophoresis. Samples were further diluted to a final
volume of 450 l with rehydration buffer (7 M urea, 2 M thiourea,
4% CHAPS, 40 mM DTT, 1% pharmalytes) coloured with a trace
amount of bromophenol blue. Immobilized pH gradient (IPGs) pH
3-11NL (24 cm) were actively rehydrated with samples at 30 V for
6 hours, followed by electrophoresis at 100 V for 2 hours, 500 V
for 1 hour, 1000 V for 1 hour, 5000 V for 12 hours and 100 V for
4 hours in the dark. After isoelectric focusing, strips were
equilibrated in 10 ml of equilibration buffer (75 mM Tris pH 8.8,
6 M urea, 30% v/v glycerol, 2% w/v SDS) for 15 minutes with 100
mg of DTT. Equilibration buffer with DTT was removed and
replaced with 10 ml equilibration buffer containing 250 mg of
iodoacetamide, and incubation was carried out for a further 15
minutes. After equilibration, strips were embedded on top of 24
cm large-format 12% SDS-PAGE gels with molten agarose (0.5%
w/v agarose in 1 Laemmli running buffer coloured with a small
amount of bromophenol blue). Second-dimension gels were
electrophoresed in an Ettan DALT Twelve electrophoresis unit at
20°C with 3 watts/gel for 45 minutes followed by 10 watts/gel for
2 hours and then 20 watts/gel until the bromophenol blue dye front
reached the bottom of the gel.
Gels were scanned with a Typhoon 9400 scanner (GE Healthcare)
using predefined settings for Cy2, Cy3 and Cy5 dyes at 100 m.
Gel images were cropped as necessary and analysed using
Progenesis SameSpots image-analysis program. Gels were aligned
with autogenerated vectors, and then individually examined to
confirm alignments, with additional vectors added where needed
to improve alignments. Images were grouped based on disease
status and comparison of SZ vs control and PD vs control conducted
using a nested ANOVA analysis using normalized spot volumes.
The criterion for significance was chosen as 0.05 and a fold-
change of at least 1.2. Further, protein spots were considered
significant only if they fulfilled these criteria for duplicate analyses
of gels from independently grown replicate cells.
Differentially expressed protein spots on the 2D-DIGE gels were
identified using mass spectrometry. Preparative gels were prepared
using pooled protein containing 67 g of protein from each sample
(600 g total protein). Gels were electrophoresed as for DIGE-labeled
material, but stained with Coomassie G-250 (0.1% w/v Coomassie
G-250, 17% w/v ammonium sulphate, 34% methanol, 3% phosphoric
acid). Coomassie-stained gels were scanned with an Odyssey infrared
scanner (Li-Cor Biosciences, USA). Spots of interest were excized
from gels, destained with 50% acetonitrile (ACN) plus 50 mM
ammonium bicarbonate (ABC) and lyophilized in a speed vac. Gel
pieces were rehydrated with 8 l of trypsin (10 ng/l in 50 mM ABC)
at 4°C for 10 minutes. An additional 12 l of 50 mM ABC buffer
was added to gel pieces, and proteins digested overnight at 37°C.
Peptides were extracted twice with 50% ACN plus 0.5% TFA, then
concentrated in a speed vac and spotted to a MALDI-TOF target
plate (0.4 l) along with 0.4 l of -cyano-4-hydroxycinnamic acid
(10 mg/ml in 50% ACN, 0.5% TFA) and allowed to dry. Spectra (500
shots) were collected using a Voyager DE STR MALDI-TOF mass
spectrometer (Applied Biosystems, USA) in reflectron mode across
700-4000 m/z. An external calibration was performed using the
peptides ACTH and angiotensin II.
Monoisotopic peak lists of calibrated spectra were generated
using DataExplorer (Applied Biosystems) and searched in
MASCOT accessed via the Australian Proteome Computational
Facility (http://www.apcf.edu.au). Searches were conducted against
all species, using a mass tolerance of ±0.5 Da, allowing for one
miscleavage, carbamidomethylation as a fixed modification, and
oxidized methionine as a variable modification. Only search results
with a statistically significant score as determined by MASCOT
were accepted as positive identifications of proteins.
Western analysis confirmation of protein expression
Protein samples were prepared from each cell line (5 g total
protein) and pooled to yield aliquots of 15 g of total protein.
Protein concentrations were determined using 2D Quant Kit (GE
Healthcare). Samples were diluted 1:8 to yield three samples of
identical volume and total protein concentration. Samples were
serially diluted in ddH2O and separated by SDS-PAGE (Cat#:
NP0329BOX, Invitrogen, CA). Western blot analysis was performed
by transferring protein samples onto PVDF membrane and probing
with goat anti-transgelin-2 (Cat#: sc-51442, Santa Cruz Inc., CA)
followed by detection with rabbit anti-goat IgG-HRP (Cat#: 61-
1620, Invitrogen, CA) by using an ECL-Plus kit (GE Healthcare).
Cell function assays
ONS cells were grown in DMEM/F12 supplemented with 10% FBS,
harvested using TrypLE Express (Invitrogen), washed in HBSS and
resuspended in 10 ml of growth medium. Cell counts were
performed using an automated particle counter (Beckman Coulter),
cells were diluted to 2.5104 cells/ml and 2500 cells (100 l) were
seeded into triplicate wells of 96-well plates [clear (absorbance-
based), white (luminescence-based) or black (fluorescence-based)
as appropriate, Nunc] and allowed to attach overnight. Medium
was changed 24 hours prior to assay. All plates and reagents were
equilibrated to RT prior to assay initiation and all results were
obtained using a Synergy II plate reader (BioTek).
Reduced GSH content was determined using modified
manufacturer-supplied protocols (GSH-Glo Glutathione Assay,
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Promega). Medium was aspirated and cells washed twice in HBSS
(100 l per well), then 50 l of` GSH reaction buffer was added to
each well and plates were incubated at RT for 15 minutes, light
protected. Luciferin detection reagent (50 l) was added and
following a further 15 minutes light-protected incubation,
luminescence intensity was recorded. MTS reagent was prepared
according to manufacturer-supplied protocols (CellTiter aqueous
MTS assay protocol, Promega), and 20 l of prepared reagent added
to each well. After incubation for 2 hours at 37°C, absorbance at
490 nm was recorded. Chymotrypsin-like proteasome activities
were measured using the supplied protocol (Cell-Based
Proteasome-Glo Assays, Promega). Briefly, cells were washed twice
in HBSS and left in 50 l of HBSS, and 50 l of prepared reagent
was added to each well. After incubation for 10 minutes at RT,
luminescence intensity was recorded. ATP levels were measured
according to manufacturer-supplied protocols (ATPlite assay kit,
Perkin Elmer). Culture medium was aspirated, and the cells were
washed twice in HBSS and subsequently left in 100 l of HBSS.
Lysis buffer (50 l) was added to each well and the plate incubated
at RT for 10 minutes, after which luciferin substrate (50 l) was
added. Following a further incubation at RT for 10 minutes,
luminescence intensity was recorded. Lactate dehydrogenase
activity was measured using manufacturer-supplied protocols
(CytoTox-ONE Homogenous Membrane Integrity Assay, Promega)
by addition of 100 l of prepared reagent to each well. After
incubation at RT for 1 hour, each well was excited at 560 nm and
intensity of fluorescence emitted at 590 nm was recorded. Caspase-
3/7 activity was measured according to manufacturer-supplied
protocols (Apo-ONE Homogenous Caspase-3/7 Assay, Promega)
via addition of 100 l of freshly prepared reagent directly to the
culture medium. After incubation for 2 hours at RT, each well was
excited at 485 nm and intensity of fluorescence emitted at 530 nm
was recorded.
For all assays, background signal was determined by including
triplicate wells containing only growth medium in parallel, and the
resulting average background reading was subtracted from all other
values for each assay. Data were normalized to DNA content,
determined using supplied protocols (CyQUANT-NF, Invitrogen;
50 l of prepared reagent per well, including medium-only control
wells). For each cell line, triplicate values from each assay were
averaged and a signal:DNA content ratio determined. Statistical
analysis was conducted using a two-tailed unpaired t-test
(GraphPad Prism 5 for Windows) on pooled data from repeated
experiments in which each cell line was assayed in triplicate.
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Clinical issue
There is an urgent need to develop new approaches for studying brain
diseases to investigate the complex gene-environment interactions that
contribute to their pathology. Schizophrenia (SZ), which is thought to be a
disorder of brain development, is a life-long mental illness affecting ~1% of
the world’s population. Despite heritability being estimated at 80%, with
family history the most important risk factor, genetic family and association
studies have failed to reveal causative genes for the disease. Parkinson’s
disease (PD) is a degenerative neurological disorder affecting 0.1% of the
world’s population. Its prevalence is age-dependent, increasing to 2% of
individuals over 60 years of age. This complex brain disease has genetic and
environmental risk factors that impact mitochondrial function, oxidative stress
and xenobiotic metabolism. Mutations in several genes cause inherited PD,
although these account for <5% of cases. It is hoped that new approaches for
studying brain diseases such as SZ and PD will reveal common steps in
heterogeneous aetiological processes that could be targets for therapeutic
intervention. Post-mortem brain samples provide some insights, but enable
the identification of endpoints of disease only and are limited in supply. Other
patient-derived cell types, such as fibroblasts and lymphoblastoid cell lines, are
easily accessible but, because they are non-neural cells, they might lack
important features necessary for understanding the biological bases of brain
diseases. 
Results
In this paper, the authors present a new patient-cell-based model for
investigating brain diseases. They derive and culture cells from the olfactory
mucosa, the sense organ of smell, which contains stem cells that continually
regenerate the organ’s sensory neurons throughout adult life. The authors use
this model to identify the genes, proteins and cellular functions that are
altered in cells derived from patients with SZ and PD by comparing them with
cells derived from healthy controls. This approach demonstrates disease-
specific differences in gene expression, protein expression and cell function
that are in line with current theories regarding the aetiologies of SZ and PD. In
cells derived from patients with SZ, the authors identify dysregulation in cell
signalling pathways of brain development, some of which have previously
been identified as candidates for disease susceptibility (such as Reelin
signalling, VDR/RXR activation, IL-8 signalling, glutathione metabolism and
ErbB signalling). Importantly, fibroblasts derived from patients with SZ did not
show these differences. In cells derived from patients with PD, the authors
identify marked changes in signalling pathways involved in oxidative stress
and xenobiotic metabolism (such as the NRF2-mediated oxidative stress
response, aryl hydrocarbon receptor signalling, glutathione metabolism and
xenobiotic metabolism signalling). Furthermore, the authors uncover new
specific molecular and genetic pathways that might expand our
understanding of disease aetiology and advance therapeutic development.
Implications and future directions
The capacity to tease out disease-specific differences using this patient-cell-
based model provides specific candidate genes and cell pathways for future
studies of brain diseases. In addition to providing informative data on SZ and
sporadic PD, this model might be useful for studying the cellular and
molecular bases of other neurological conditions. This system can be applied
to improve our understanding of disease aetiology, the development of new
diagnostics and drug discovery.
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